TCG Crossover Management
PALO ALTO, CAfiles as TCG Crossover Management, LLC
$4.2bn in 54 US stocks at the end of 30 June 2026. The top 10 are 57.4% of the money. It changed about 16.8% of the portfolio this quarter.
Value
$4.2bn
Stocks
54
Top 10 share
57.4%
Turnover
16.8%
What changed this quarter
New
Bought for the first time this quarter.
- ZAI LABZLAB2.8% of the fund
- Aura BiosciencesAURA1.6% of the fund
- First Tracks BiotherapeuticsTRAX1.4% of the fund
- Editas MedicineEDIT0.9% of the fund
- PharvarisPHVS0.8% of the fund
- InflaRxIFRX0.8% of the fund
- AltimmuneALT0.7% of the fund
- Aktis OncologyAKTS0.5% of the fund
- Forte Biosciences0.5% of the fund
- Research Alliance Corp IIIRACC0.1% of the fund
- JATT II AcquisitionJATT<0.1% of the fund
- Eikon TherapeuticsEIKN<0.1% of the fund
Added
Bought more of a stock they already held.
- Avalo TherapeuticsAVTX1.3% of the fund+309%
- Monopar TherapeuticsMNPR0.5% of the fund+54%
Cut
Sold some of their stake.
- Abivax SAABVX19.2% of the fund-7%
- Tango TherapeuticsTNGX6.8% of the fund-14%
- Revolution MedicinesRVMD1.5% of the fund-41%
- LB PharmaceuticalsLBRX1.1% of the fund-21%
- BiohavenBHVN0.6% of the fund-62%
- ALX Oncology HoldingsALXO0.3% of the fund-57%
- Entrada TherapeuticsTRDA0.2% of the fund-54%
- ArvinasARVN0.1% of the fund-70%
Sold out
Sold their entire stake.
- Centessa Pharmaceuticals-100%
- Fulcrum TherapeuticsFULC-100%
- LiquidiaLQDA-100%
- UroGen PharmaURGN-100%
- Structure TherapeuticsGPCR-100%
- Upstream BioUPB-100%
- Vistagen TherapeuticsVTGN-100%
Holdings
- Abivax SAABVX
- Share
- 19.2%
- Value
- $801m
- Shares
- 6,007,834
-7%
- ZAI LABZLAB
- Share
- 2.8%
- Value
- $117m
- Shares
- 6,137,627
New
- First Tracks BiotherapeuticsTRAX
- Share
- 1.4%
- Value
- $58m
- Shares
- 2,895,304
New
- Forte Biosciences
- Share
- 0.5%
- Value
- $20m
- Shares
- 920,000
New
- Research Alliance Corp IIIRACC
- Share
- 0.1%
- Value
- $5m
- Shares
- 500,000
New
- JATT II AcquisitionJATT
- Share
- <0.1%
- Value
- $2m
- Shares
- 200,000
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Abivax SAABVX | 19.2% | $801m | 6,007,834 | -7% |
| Tango TherapeuticsTNGX | 6.8% | $284m | 9,081,201 | -14% |
| CG OncologyCGON | 6.3% | $261m | 3,670,206 | Held |
| Cogent BiosciencesCOGT | 4.5% | $188m | 4,854,436 | Held |
| ImmunovantIMVT | 4.1% | $172m | 4,457,988 | Held |
| Spyre TherapeuticsSYRE | 4.1% | $169m | 1,900,582 | Held |
| Dianthus TherapeuticsDNTH | 3.9% | $163m | 1,676,624 | Held |
| Mirum PharmaceuticalsMIRM | 3.0% | $124m | 1,062,049 | Held |
| ZAI LABZLAB | 2.8% | $117m | 6,137,627 | New |
| Amylyx PharmaceuticalsAMLX | 2.7% | $112m | 6,243,812 | Held |
| Monte Rosa TherapeuticsGLUE | 2.7% | $112m | 4,622,151 | Held |
| Biocryst PharmaceuticalsBCRX | 2.6% | $110m | 11,020,968 | Held |
| Vor BiopharmaVOR | 2.5% | $104m | 5,673,078 | Held |
| Tyra BiosciencesTYRA | 2.5% | $104m | 3,248,980 | Held |
| Dyne TherapeuticsDYN | 2.5% | $103m | 4,615,144 | Held |
| Disc MedicineIRON | 2.4% | $98m | 1,341,862 | Held |
| Relay TherapeuticsRLAY | 1.9% | $80m | 4,273,356 | Held |
| SavaraSVRA | 1.8% | $76m | 12,362,205 | Held |
| Aura BiosciencesAURA | 1.6% | $68m | 9,533,333 | New |
| Revolution MedicinesRVMD | 1.5% | $64m | 340,899 | -41% |
| First Tracks BiotherapeuticsTRAX | 1.4% | $58m | 2,895,304 | New |
| Kodiak SciencesKOD | 1.4% | $56m | 1,445,538 | Held |
| Avalo TherapeuticsAVTX | 1.3% | $56m | 3,017,120 | +309% |
| LB PharmaceuticalsLBRX | 1.1% | $47m | 1,447,310 | -21% |
| Century TherapeuticsIPSC | 1.0% | $43m | 17,754,430 | Held |
| Tectonic TherapeuticTECX | 1.0% | $41m | 1,204,891 | Held |
| XencorXNCR | 0.9% | $39m | 2,452,138 | Held |
| SurrozenSRZN | 0.9% | $38m | 1,473,101 | Held |
| Editas MedicineEDIT | 0.9% | $36m | 11,111,111 | New |
| MBX BiosciencesMBX | 0.9% | $36m | 650,000 | Held |
| PharvarisPHVS | 0.8% | $35m | 1,008,229 | New |
| Silence TherapeuticsSLN | 0.8% | $33m | 3,033,560 | Held |
| InflaRxIFRX | 0.8% | $32m | 14,500,000 | New |
| AltimmuneALT | 0.7% | $30m | 10,000,000 | New |
| Janux TherapeuticsJANX | 0.7% | $27m | 1,789,617 | Held |
| Perspective TherapeuticsCATX | 0.6% | $27m | 7,915,567 | Held |
| AgomAb Therapeutics NVAGMB | 0.6% | $27m | 2,053,233 | Held |
| BiohavenBHVN | 0.6% | $26m | 1,779,952 | -62% |
| Aktis OncologyAKTS | 0.5% | $22m | 696,560 | New |
| AlectorALEC | 0.5% | $20m | 10,000,000 | Held |
| Forte Biosciences | 0.5% | $20m | 920,000 | New |
| Monopar TherapeuticsMNPR | 0.5% | $19m | 203,327 | +54% |
| Ocular TherapeutixOCUL | 0.4% | $16m | 1,647,752 | Held |
| ADC Therapeutics SAADCT | 0.3% | $12m | 11,390,175 | Held |
| ALX Oncology HoldingsALXO | 0.3% | $12m | 5,655,487 | -57% |
| Entrada TherapeuticsTRDA | 0.2% | $8m | 1,060,230 | -54% |
| Cullinan TherapeuticsCGEM | 0.2% | $7m | 406,786 | Held |
| ArvinasARVN | 0.1% | $6m | 707,098 | -70% |
| Korro BioKRRO | 0.1% | $5m | 416,301 | Held |
| Research Alliance Corp IIIRACC | 0.1% | $5m | 500,000 | New |
| LeonaBioLONA | 0.1% | $4m | 464,398 | Held |
| JATT II AcquisitionJATT | <0.1% | $2m | 200,000 | New |
| Context TherapeuticsCNTX | <0.1% | $1m | 2,682,696 | Held |
| Eikon TherapeuticsEIKN | <0.1% | $494,621 | 37,902 | New |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 375.2% since 30 June 2025.
Where the money is
Health care77.4%
Financial services0.1%
Other22.5%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.